
Atheric™ Pharmaceutical LLC, an American biopharmaceutical company, focuses on developing and commercializing re-purposed drugs to combat Zika and other Flavivirus diseases.
Atheric Pharmaceutical LLC is an American biopharmaceutical company dedicated to the rapid development and commercialization of re-purposed drugs to prevent and treat Zika and other Flavivirus diseases. Their lead products are reformulated broad-spectrum antiviral drugs that inhibit autophagy-dependent viral replication and other antiviral pathways, aiming to provide broad-spectrum medical countermeasures for neglected tropical diseases.
Atheric Pharmaceutical has made significant strides in addressing public health challenges posed by Flavivirus diseases. By focusing on re-purposed drugs, the company accelerates the availability of effective treatments, contributing to global health security. Their innovative approach has positioned them as a key player in the fight against neglected tropical diseases.

Aether Therapeutics

Atea Pharmaceuticals
ateapharma.com

Aria Pharmaceuticals

Aristea Therapeutics

Archean Biologics

Veloce BioPharma

Anthera Pharmaceuticals
anthera.com

Arisan Therapeutics
arisanthera.com

Globavir Biosciences

Underdog Pharmaceuticals
cyclaritytx.com

Kathera Bioscience
katherabio.com

Aztherapies

Accuitis
accuitis.com

Arete Therapeutics

Emergo Therapeutics
Companies similar to Atheric Pharmaceutical include Aether Therapeutics, Atea Pharmaceuticals, Aria Pharmaceuticals and Aristea Therapeutics.
Atheric Pharmaceutical was founded in 2013.
Atheric Pharmaceutical's headquarters is located in Troy, VT, US.
Atheric Pharmaceutical's most recent funding round was for $100k (USD) in September 2016.
As of Sep 7, 2016, Atheric Pharmaceutical has raised a total of $100k (USD).
Atheric Pharmaceutical has 7 employees as of Feb 5, 2024.